Medifast, Inc. (MED)
| Market Cap | 123.34M -19.6% |
| Revenue (ttm) | 316.93M -34.0% |
| Net Income | -25.60M |
| EPS | -2.32 |
| Shares Out | 10.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 80,494 |
| Open | 12.08 |
| Previous Close | 11.99 |
| Day's Range | 11.90 - 12.13 |
| 52-Week Range | 9.22 - 14.67 |
| Beta | 0.73 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 2, 2026 |
About MED
Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions for weight loss in the United States. The company offers weight loss, weight management, and healthy living products comprising bars, cereals, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, soups, amino acid blends, whey protein, hot beverages, brownies, and mini meals under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTI... [Read more]
Financial Performance
Financial StatementsNews
Ocius Technology to Add Sonar Systems to Bluebottle Fleet: NYSE Content Update
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept.
Medifast announces launch of Medifast Metabolic Health Institute
Medifast (MED) has announced the launch of the Medifast Metabolic Health Institute, established to advance metabolic health through research and evidence-based education. “Metabolic dysfunction is one...
Medifast® Announces the Launch of the Medifast Metabolic Health Institute™
BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) has announced the launch of the Medifast Metabolic Health Institute, established to advance metabolic health through rigorous research and credib...
Medifast reports Q2 EPS (28c) vs (22c) last year
Reports Q2 revenue $76.4M vs $105.6M last year. Nick Johnson, Chief Executive Officer, commented, “In the second quarter, we continued to see signs of a turnaround in our business. Revenue…
Medifast sees Q3 EPS (65c)-(15c), one estimate (62c)
Sees Q3 revenue $60M-$80M, one estimate $67.7M.
Medifast raises FY26 EPS view to ($1.75)-(25c) from ($2.75)-($1.55)
One estimate ($1.85). Backs FY26 revenue $270M-$300M, one estimate $279.7M.
Medifast Earnings Call Transcript: Q2 2026
Revenue stabilized sequentially, with coach productivity up 41% year-over-year despite a 48.7% drop in active coaches. Q2 revenue was $76.4 million, net loss $3.1 million, and profitability is targeted for Q4 2026, supported by new product launches and cost-saving initiatives.
Medifast Earnings release: Q2 2026
Medifast released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Medifast Slides: Q2 2026
Medifast has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
Medifast Quarterly report: Q2 2026
Medifast has published its Q2 2026 quarterly earnings report on August 3, 2026.
Medifast Announces Second Quarter 2026 Financial Results
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, today reported results for the second qua...
Medifast to Announce Financial Results for the Second Quarter Ended June 30, 2026
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, will announce financial results...
Medifast announces launch of Trilivy metabolic health system
Medifast (MED) announced the launch of Trilivy, a comprehensive metabolic health system uniquely designed to support healthy lifestyle change. The launch also introduces newly formulated meal replacem...
Medifast® Enters a New Era: Introducing Trilivy™, a Science-Backed Metabolic Health System
BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) today announced the launch of Trilivy, a comprehensive metabolic health system uniquely designed to support healthy lifestyle change. The launch ...
What Science-Backed Subscription Health Programs Measure Differently
The weight loss and weight management market was valued at $31.07 billion in 2025 A program can describe its results as clinically meaningful without specifying what was measured, how it was measured...
Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management
OPTAVIA's clinical program reduces visceral fat 14% and retains 98% lean mass, directly addressing the metabolic impact of perimenopause and menopause.
Medifast names Nicholas Johnson as CEO
Medifast (MED) “announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will…
Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer
BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) today announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson w...
The Human Layer in Weight Management: What OPTAVIA's Coaching Model Is Built to Do
A randomized controlled trial published in Obesity Science & Practice found that clients on the OPTAVIA Optimal Weight 5 & 1 Plan® who worked with a coach lost significantly more weight and fat than t...
Weight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term Outcomes
70% of users discontinued use of lifestyle behavior and health apps within the first 100 days (Kidman PG, et al., 2024) Early weight loss at week four is a strong predictor of clinically relevant outc...
Peer-Reviewed Research Is Redefining Weight Loss Program Standards
The global weight loss industry was valued at $16.3 billion in 2025, yet peer-reviewed clinical validation of program outcomes remains uneven across the category Randomized controlled trials control f...
Peer-Reviewed Research Shows Structured Meal Replacement Programs Support Visceral Fat Reduction and Lean Mass Preservation
Body composition, specifically visceral fat levels and lean mass, plays a meaningful role in long-term metabolic health (Serra MC, et al., 2019) Structured plans, habit building, and dedicated coach s...
Medifast Earnings Call Transcript: Q1 2026
Sequential revenue growth returned for the first time in three years, driven by a 19% year-over-year increase in coach productivity and strong referral activity, despite a 34% revenue decline and ongoing disruption from GLP-1 medications. Profitability improvements are targeted for Q4 2026, with a new product launch and cost savings expected to support future growth.
Medifast Earnings release: Q1 2026
Medifast released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
Medifast Slides: Q1 2026
Medifast has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 4, 2026.